Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 1
1976 3
1977 3
1978 1
1979 1
1980 2
1981 4
1982 3
1983 5
1984 8
1985 2
1986 7
1987 7
1988 4
1989 14
1990 8
1991 8
1992 13
1993 14
1994 11
1995 8
1996 10
1997 10
1998 13
1999 18
2000 24
2001 17
2002 15
2003 18
2004 16
2005 17
2006 30
2007 30
2008 27
2009 23
2010 33
2011 40
2012 41
2013 39
2014 42
2015 58
2016 44
2017 57
2018 47
2019 46
2020 58
2021 55
2022 47
2023 50
2024 22

Text availability

Article attribute

Article type

Publication date

Search Results

951 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Thrombocythemia 3"
Page 1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Free article. Review.
MUTATIONS: SRSF2, ASXL1, and U2AF1-Q157 mutations predict inferior survival in PMF; RAS/CBL mutations predict resistance to ruxolitinib therapy. ...RISK STRATIFICATION: Contemporary prognostic systems include GIPSS (genetically-inspired prognostic scoring …
MUTATIONS: SRSF2, ASXL1, and U2AF1-Q157 mutations predict inferior survival in PMF; RAS/CBL mutations predict resistance to ru …
Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Tefferi A, Barbui T. Tefferi A, et al. Am J Hematol. 2023 Sep;98(9):1465-1487. doi: 10.1002/ajh.27002. Epub 2023 Jun 26. Am J Hematol. 2023. PMID: 37357958 Review.
CYTOGENETICS: Abnormal karyotype is seen in 15%-20% of patients with the most frequent sole abnormalities being +9 (5%), loss of chromosome Y (4%), +8 (3%), and 20q- (3%). MUTATIONS: Over 50% of patients harbor DNA sequence variants/mutations other than JAK2, with t …
CYTOGENETICS: Abnormal karyotype is seen in 15%-20% of patients with the most frequent sole abnormalities being +9 (5%), loss of chromosome …
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera.
Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, Sordi B, Szuber N, Rotunno G, Pacilli A, Hanson CA, Ketterling RP, Pardanani A, Gangat N, Vannucchi AM. Tefferi A, et al. Br J Haematol. 2020 Apr;189(2):291-302. doi: 10.1111/bjh.16380. Epub 2020 Jan 16. Br J Haematol. 2020. PMID: 31945802 Free article.
Survival prediction in essential thrombocythaemia (ET) and polycythaemia vera (PV) is currently based on clinically-derived variables; we examined the possibility of integrating genetic information for predicting survival. ...HR-based risk point allocation al …
Survival prediction in essential thrombocythaemia (ET) and polycythaemia vera (PV) is currently based on clinically-derived va …
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, Rambaldi A, Caramella M, Komrokji R, Gotlib J, Kiladjian JJ, Cervantes F, Devos T, Palandri F, De Stefano V, Ruggeri M, Silver RT, Benevolo G, Albano F, Caramazza D, Merli M, Pietra D, Casalone R, Rotunno G, Barbui T, Cazzola M, Vannucchi AM. Passamonti F, et al. Leukemia. 2017 Dec;31(12):2726-2731. doi: 10.1038/leu.2017.169. Epub 2017 May 31. Leukemia. 2017. PMID: 28561069
Median survival of the whole cohort was 9.3 years (95% CI: 8-not reached-NR-). Through penalized Cox regressions we identified negative predictors of survival and according to beta risk coefficients we assigned 2 points to hemoglobin level <11 g/dl, to circulatin …
Median survival of the whole cohort was 9.3 years (95% CI: 8-not reached-NR-). Through penalized Cox regressions we identified negati …
Myeloproliferative Neoplasms with Monocytosis.
Morsia E, Gangat N. Morsia E, et al. Curr Hematol Malig Rep. 2022 Feb;17(1):46-51. doi: 10.1007/s11899-021-00660-2. Epub 2021 Nov 13. Curr Hematol Malig Rep. 2022. PMID: 34773576 Review.
Prognostically relevant clinical and genetic parameters have been incorporated into mutation-enhanced scoring systems (MIPSS70-plus version 2.0, MIPSS-ET/PV). In the current review, we describe clinical and pathological features along with prognostic significance of …
Prognostically relevant clinical and genetic parameters have been incorporated into mutation-enhanced scoring systems (MIPSS70 …
Developments in diagnosis and treatment of essential thrombocythemia.
Mora B, Passamonti F. Mora B, et al. Expert Rev Hematol. 2019 Mar;12(3):159-171. doi: 10.1080/17474086.2019.1585239. Epub 2019 Mar 13. Expert Rev Hematol. 2019. PMID: 30793984 Review.
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by thrombocytosis, increased risk of thrombotic/hemorrhagic events and clonal evolution into blast phase or myelofibrosis. ...New insights into the molecular pathogenesis of the di …
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by thrombocytosis, increased risk of thr …
Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A, Barbui T. Tefferi A, et al. Mayo Clin Proc. 2015 Sep;90(9):1283-93. doi: 10.1016/j.mayocp.2015.05.014. Mayo Clin Proc. 2015. PMID: 26355403 Review.
Bone marrow (BM) morphologic features remain the cornerstone of diagnosis in both essential thrombocythemia (ET) and polycythemia vera (PV). In addition, recently discovered mutations, such as JAK2, CALR, and MPL, have proven useful in facilitating the diagnostic process. …
Bone marrow (BM) morphologic features remain the cornerstone of diagnosis in both essential thrombocythemia (ET) and polycythemia ver …
Essential thrombocythaemia.
Tobelem G. Tobelem G. Baillieres Clin Haematol. 1989 Jul;2(3):719-28. doi: 10.1016/s0950-3536(89)80040-x. Baillieres Clin Haematol. 1989. PMID: 2505875 Review.
Essential thrombocythaemia (ET) is a rare clonal myeloproliferative disorder characterized by a persistent increase in platelet count. ...The use of recombinant alpha-interferon has recently been proposed and is under investigation. The pathogenesis of thrombocytosis …
Essential thrombocythaemia (ET) is a rare clonal myeloproliferative disorder characterized by a persistent increase in platelet count …
BCR::ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera.
Khodier M, Gadó K. Khodier M, et al. Physiol Int. 2023 Aug 31;110(3):227-250. doi: 10.1556/2060.2023.00261. Print 2023 Sep 5. Physiol Int. 2023. PMID: 37651280 Review.
There are many overlapping symptoms of Philadelphia negative MPNs, such as fatigue, night sweats, hepatosplenomegaly and circulatory symptoms due to increased cell numbers. Total Symptom Score of the MPN Symptom Assessment Form is used to assess symptom burden on patients. …
There are many overlapping symptoms of Philadelphia negative MPNs, such as fatigue, night sweats, hepatosplenomegaly and circulatory symptom …
Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Shallis RM, Zeidan AM, Wang R, Podoltsev NA. Shallis RM, et al. Hematol Oncol Clin North Am. 2021 Apr;35(2):177-189. doi: 10.1016/j.hoc.2020.11.005. Epub 2021 Jan 4. Hematol Oncol Clin North Am. 2021. PMID: 33641862 Review.
Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) comprise the BCR-ABL-negative classical myeloproliferative neoplasms (MPNs). ...PV and ET have an incidence of 0.5 to 4.0 and 1.1 to 2.0 cases per 100,000 person-years, respectively, an …
Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) comprise the BCR-ABL-negative classical myelo …
951 results